重组人促红细胞生成素—α治疗癌性贫血的疗效和安全性(1)
摘要：目的 观察重组人促红细胞生成素-α(rhEPO)治疗癌性贫血的最佳时间、疗效以及安全性。方法 临床纳入我院70例经病理学检查确诊为癌症并伴有非髓性贫血患者，化疗前患者血红蛋白(Hb)水平100～120g/L。根据患者rhEPO使用时间的不同分为早使用组与晚使用组。早使用组在化疗的同时即给予rhEPO皮下注射，晚实验组在Hb<90g/L时给予rhEPO皮下注射。对于治疗期间出现铁缺乏、疗效不明显的患者加用琥珀酸亚铁0.1g口服，3次/d。观察两组患者治疗前后Hb以及血细胞比容(HCT)水平，对比两组患者治疗前期不良反应发生情况。结果 治疗0～4w、5～8w、9～12w，早使用组Hb水平为(116.8±6.7)g/L、(120.3±8.2)g/L、(128.1±10.3)g/L，HCT水平分别为(0.37±0.09)、(0.39±0.06)、(0.41±0.04)；晚使用组Hb水平为(108.6±5.9)g/L、(107.3±9.9)g/L、(105.0±8.7)g/L，HCT水平分别为(0.31±0.03)、(0.29±0.05)、(0.27±0.01)，组间差异均有显著性(P<0.05)。两组患者治疗期间均未发生严重不良反应，主要不良反应为低热、皮疹、乏力以及食欲下降等。结论 化疗同时即给予rhEPO注射，能够有效提高患者Hb以及Hct水平，改善患者贫血，且药物不良反应较低。
关键词：重组人促红细胞生成素-α；癌性贫血；疗效；安全性
Abstract：Objective To observe the best time and efficacy and safety effects of recombinant human erythropoietin alpha(rhEPO)for the treatment of anemia of cancer.Methods 70 cases of patients，pathologically diagnosed as cancer accompanied by non myeloid anemia，were selected in our hospital.Hemoglobin(Hb)level of Pre chemotherapy patients were 100～120g/L.According to the different rhEPO patients using time，they were divided into the early and late use group.Early use of group at the time of chemotherapy is given by subcutaneous injection of rhEPO，late in the experiment group Hb<90g/L when it was given by subcutaneous injection of rhEPO.For treatment during iron deficiency，the effect was not obvious in patients with 0.1g by ferrous succinate orally，3 times a day.Two groups were observed before and after treatment in patients with Hb and the hematocrit(HCT)levels，compared two groups of patients with the treatment of early stage the occurrence of adverse reactions.Results The treatment of 0～4 weeks，5～8 weeks，9～12 weeks，Hb level of early use of group were(116.8±6.7)g/L，(120.3±8.2)g/L，(128.1±10.3)g/L，HCT levels were(0.37±0.09)and(0.39±0.06)and(0.41±0.04)；Hb level of late use groups were(108.6±5.9)g/L，(107.3±9.9)g/L，(105±8.7)g/L，HCT levels were(0.31±0.03)and(0.29±0.05)and(0.27±0.01)，the difference between groups was significant(P<0.05).During the period of treatment，the patients of two groups were no serious adverse reactions，the main adverse reactions were fever，rash，fatigue and decreased appetite，etc.Conclusion Chemotherapy given rhEPO injection can effectively improve the patients with Hb and Hct level of patients with anemia，improve，and drug adverse reaction is lower.
Key words：Recombinant human erythropoietin alpha；Anemia of cancer；Efficacy；Safety
贫血属于癌症患者较为多见的一类并发症。根据NCI以及EORTC的相关标准，临床上根据血红蛋白的水平可以将贫血分为轻度贫血(Hb在100～120 g/L)、中度贫血(Hb在80～100 g/L)、重度贫血(Hb<80g/L)[1]。目前研究表明，当肿瘤处于进展期或进行化疗、放疗时，患者贫血的发生率显著升高[2，3]。重组人促红细胞生成素-α(rhEPO)属于临床上常见的一种改善贫血的药物，其能够以非输血形式促进机体内红细胞的生成，以起到改善患者贫血的目的[4]。为进一步观察rhEPO对治疗癌性贫血的最佳时间、疗效以及安全性。笔者对我院70例癌性贫血患者进行了临床分组观察，现报告如下。, 百拇医药(周云凤)
关键词：重组人促红细胞生成素-α；癌性贫血；疗效；安全性
Abstract：Objective To observe the best time and efficacy and safety effects of recombinant human erythropoietin alpha(rhEPO)for the treatment of anemia of cancer.Methods 70 cases of patients，pathologically diagnosed as cancer accompanied by non myeloid anemia，were selected in our hospital.Hemoglobin(Hb)level of Pre chemotherapy patients were 100～120g/L.According to the different rhEPO patients using time，they were divided into the early and late use group.Early use of group at the time of chemotherapy is given by subcutaneous injection of rhEPO，late in the experiment group Hb<90g/L when it was given by subcutaneous injection of rhEPO.For treatment during iron deficiency，the effect was not obvious in patients with 0.1g by ferrous succinate orally，3 times a day.Two groups were observed before and after treatment in patients with Hb and the hematocrit(HCT)levels，compared two groups of patients with the treatment of early stage the occurrence of adverse reactions.Results The treatment of 0～4 weeks，5～8 weeks，9～12 weeks，Hb level of early use of group were(116.8±6.7)g/L，(120.3±8.2)g/L，(128.1±10.3)g/L，HCT levels were(0.37±0.09)and(0.39±0.06)and(0.41±0.04)；Hb level of late use groups were(108.6±5.9)g/L，(107.3±9.9)g/L，(105±8.7)g/L，HCT levels were(0.31±0.03)and(0.29±0.05)and(0.27±0.01)，the difference between groups was significant(P<0.05).During the period of treatment，the patients of two groups were no serious adverse reactions，the main adverse reactions were fever，rash，fatigue and decreased appetite，etc.Conclusion Chemotherapy given rhEPO injection can effectively improve the patients with Hb and Hct level of patients with anemia，improve，and drug adverse reaction is lower.
Key words：Recombinant human erythropoietin alpha；Anemia of cancer；Efficacy；Safety
贫血属于癌症患者较为多见的一类并发症。根据NCI以及EORTC的相关标准，临床上根据血红蛋白的水平可以将贫血分为轻度贫血(Hb在100～120 g/L)、中度贫血(Hb在80～100 g/L)、重度贫血(Hb<80g/L)[1]。目前研究表明，当肿瘤处于进展期或进行化疗、放疗时，患者贫血的发生率显著升高[2，3]。重组人促红细胞生成素-α(rhEPO)属于临床上常见的一种改善贫血的药物，其能够以非输血形式促进机体内红细胞的生成，以起到改善患者贫血的目的[4]。为进一步观察rhEPO对治疗癌性贫血的最佳时间、疗效以及安全性。笔者对我院70例癌性贫血患者进行了临床分组观察，现报告如下。, 百拇医药(周云凤)
参见：首页 > 医疗版 > 疾病专题 > 血液内科 > 贫血